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https://doi.org/10.1016/j.celrep.2021.109131SUMMARYCommunication between biological components is critical for homeostasis maintenance among the conver-
gence of complicated bio-signals. For therapeutic nanoparticles (NPs), the general lack of effective communi-
cation mechanisms with the external cellular environment causes loss of homeostasis, resulting in deprived
autonomy, severe macrophage-mediated clearance, and limited tumor accumulation. Here, we develop a
multistage signal-interactive system on porous silicon particles through integrating the Self-peptide and Tyr-
Ile-Gly-Ser-Arg (YIGSR) peptide into a hierarchical chimeric signaling interface with ‘‘don’t eat me’’ and ‘‘eat
me’’ signals. This biochemical transceiver can act as both the signal receiver for amantadine to achieve NP
transformation and signal conversion as well as the signal source to present different signals sequentially by
reversible self-mimicking. Compared with the non-interactive controls, these signal-interactive NPs loaded
with AS1411 and tanespimycin (17-AAG) as anticancer drugs improve tumor targeting 2.8-fold and tumor sup-
pression 6.5-fold and showed only 51% accumulation in the liver with restricted hepatic injury.INTRODUCTION
Communication is universal in biological systems (Perbal, 2003).
Biomolecule interactions (such as antigen receptor recognition),
signal pathway conduction, and even cell-level behavior that re-
lates to development, homeostasis, and immunity are all
communication processes (Sadelain et al., 2013; Bray, 1998;
Bloemendal and K€uck, 2013). Traditional therapeutic strategies
are also achieved by intervening in the communication with bio-
molecules (mainly proteins, such as receptors, enzymes, and
iron channels) via drug molecules (Zhu et al., 2009; Scott et al.,
2016). Nevertheless, due to the lack of a direct communicationThis is an open access article under the CC BY-Nmechanism on the cellular level, traditional drugs usually lack
specific targeting capacity and cause drug-originated systemic
toxic effects (Peer et al., 2007). From this perspective, nanopar-
ticles (NPs) emerged as a kind of signal vehicle for conducting
communication with cells (Peer et al., 2007; Shi et al., 2017;
Yang et al., 2019). Owing to the versatile physical and structural
advantages of NPs, combined with the immense developments
of modification strategies, it is possible to intervene and regulate
cellular behavior or even fate by specifically designed NPs (Tang
et al., 2014; Trappmann et al., 2012; Mohammadinejad et al.,
2019; Bodelón et al., 2017; Rosenblum et al., 2018). However,




OPEN ACCESStreatment, the situation is almost reversed. The fate of NPs de-
pends more on the external bio-environment, resulting in severe
clearance during blood circulation and limited tumor accumula-
tion (Feliu et al., 2016; Bertrand et al., 2017; Corbo et al., 2016;
Wilhelm et al., 2016).
Although the existing biological barriers, especially the mono-
nuclear phagocyte system, are the main reason for the problems
of targeting, the limits in understanding and positioning of nano-
materials themselves also restrict the development process
(Blanco et al., 2015). Conventionally, under the framework of
the ‘‘delivery system,’’ NPs are designed to be chosen by the
cells, which means the cells have higher priority and initiative
than that of NPs during the NP-cell interactions. In this case,
the autonomy of NPs will be subordinate to external cell behav-
iors. Moreover, the inevitable immunogenicity of foreign NPs
leads to various immune defenses, which further deprive the au-
tonomy of NPs (Li et al., 2020; Gustafson et al., 2015. Thus, it is
difficult to maintain the homeostasis of NPs and to manipulate
the fate of NPs in vivo (Moghimi and Simberg, 2017; Tsoi et al.,
2016). Conservatively, the autonomy of the NPs is hardly to be
improved directly by adding functionality or complexity without
a NP-cell communication vision (Wilhelm et al., 2016). In the bio-
logical environment, signal interactions by communication be-
tween individuals are critical for homeostasis maintenance
(Mondal et al., 2011). Therefore, NP-cell communication requires
that NPs can interact with the cells in a signal-interactivemanner,
rather than unilaterally receiving signals from cells. However,
limited by the current development stage ofmaterials, it is almost
unachievable to construct an artificial surface on NPs with a dy-
namic cell-like communication mechanism (Noireaux et al.,
2011; Salehi-Reyhani et al., 2017). Therefore, we hypothesize
that an alternative way to achieve this purpose is through modu-
lating in order the signal-presenting process by sequentially inte-
grating different signal models. Based on this understanding, the
NPs described here were designed to combine the attributes of
‘‘signal receiver,’’ ‘‘signal source,’’ and ‘‘signal processor,’’ with
a ‘‘presenting-receiving-responding-presenting’’ pattern to pro-
cess signals, termed as a multistage signal-interactive system.
In this study, we chose the Self-peptide and the pentapeptide
Tyr-Ile-Gly-Ser-Arg (YIGSR) sequence-contained peptide as the
signal-source modules, which can present ‘‘don’t eat me’’ and
‘‘eat me’’ signals to cells, respectively (Rodriguez et al., 2013;
Sarfati et al., 2011). The Self-peptide contains a functional domain
of CD47glycoprotein, which can act as a ‘‘marker of self’’ to inhibit
phagocyte clearance byCD47-SIRPa (signal regulatory protein-a)
interaction. It is reported that the Self-peptide-coated particles
can also inhibit mouse macrophage uptake through inhibiting
cells’ contractility-driven uptake by SIRPa signaling (Rodriguez
et al., 2013). In addition, the YIGSR peptide can help NPs target
to cancer cells that overexpress the relevant receptor b1-integrine
(Sarfati et al., 2011). To integrate these two kinds of signal mod-
ules in correct order, we grafted the Self-peptidewith b-cyclodex-
trine (b-CD) to obtain b-CD-conjugated Self-peptide (termed as
b-CDSelf-peptide). The b-CD terminus can form a stable CD-
phenol complexwith the Tyr in the YIGSRpeptide through self-as-
sembly (Chen and Jiang, 2011; Shanmugam et al., 2008;
Bouhadiba et al., 2017). The assembled chimeric peptide causes
disfunction of YIGSR targeting to b1-integrine and synchronously2 Cell Reports 35, 109131, May 25, 2021implements self-mimicking, both of which are favorable for
enhancing the homeostasis and reducing the immunogenicity of
NPs, consequently leading to enhanced tumor accumulation
(Graf et al., 1987; Dvir et al., 2010). Moreover, the CD-Tyr complex
can also act as a receiving module to exogenous signal of aman-
tadine (Ad), which can disintegrate the CD-Tyr complex by host-
guest competition (Figure S1A) (Hu et al., 2014; Smiljanic et al.,
2006; Lai et al., 2017). Next, the modified NPs can respond to
this Ad signal with in situ particle transformation and surface-
signal conversion. This process will recover the targeting capacity
of YIGSR sequence and facilitate cancer cell uptake of NPs by
presenting an ‘‘eat me’’ signal. The whole multistage signal-inter-
active process is a reversible self-mimicking process, termed here
as the RevSeMicNP system (Figures S1B and S1C). After loading
tanespimycin (17-AAG) and AS1411 as model drugs, we demon-
strate the effectiveness and necessity of the signal-interactive
mechanism for communication, which can efficiently manipulate
the NP-cell interactions and regulate biodistribution behavior of
the NPs by in vitro and in vivo studies (Figure S1D).
RESULTS
Synthesis and characterizations of the functionalized
NPs with chimeric signal peptides
To fabricate the signal modules for communication, the azide
polyethylene glycol (N3-PEG4) terminus-functionalized (N-
Term.)-GGGGYIGSR peptide (YIGSR for short) and N3-PEG4
(N-Term.)-Self peptide (with amino acid sequence TCEVTEL-
TREGETIIELK) were prepared by standard solid-phase peptide
synthesis, and the b-CD terminus was then conjugated to the
azido-Self peptide to obtain the b-CDSelf-peptide by bio-
orthogonal strain-promoted alkyne-azide cycloaddition (Figures
S2A and S2B). The relevant data of liquid chromatography-mass
spectrometry (LC-MS) and matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry are
shown in Figures S2C and S2D. Computational mimicking dem-
onstrates the Self-peptide tends to fold from ‘‘stretched’’ state
into ‘‘bend’’ conformation (Figure 1A). Figure 1B details the inter-
actions between the Self-peptide and SIRPa on the contact
interface and the binding: (1) intra-peptide ionic interaction be-
tween Glu 6 and Arg 9 of the peptide helps Arg 9 position to
hydrogen bond (3.3 Å) toward the main chain carboxyl oxygen
of residue Ala 86 of SIRPa; (2) Thr 88 residue hydroxyl of SIRPa
serves as hydrogen bond (2.9 Å) donor to nitrogen on the peptide
Glu 6 main chain, which also forms hydrogen bond (3.3 Å) with
Glu 110 of SIRPa; and (3) Thr 5 of the peptide also forms weak
hydrogen bond (3.6 Å) with side residue of Tyr 90 of SIRPa.
The computational docking disclosed the possible binding
pose and relative position of the Self-peptide and receptor,
showing three different but possible binding complexes
(Figure 1C). Figure 1Ca demonstrates the most likely binding
pose of experimental peptide based on the docking score and
rational analysis. Figures 1Cb and 1Cc enumerate another
possible pose of the experimental peptide.
The construction process of RevSeMicNPs is shown in
Figure S2E. The size and zeta (z)-potential changes of NPs dur-
ing the fabrication process and the relevant morphological fea-
tures are shown in Figures 1D and 1E and Figure S3A. Taking
(legend on next page)






OPEN ACCESSadvantage of the chemical-engineering-available surface area
and good biocompatibility, undecylenic-acid-modified thermally
hydrocarbonized porous silicon NPs (termed as UnPSi NPs)
were used as a scaffold to construct the RevSeMicNP system
(Li et al., 2018; Zhang et al., 2017). First, polyethylenimine (PEI)
was bonded onto the surface of PSi NPs to increasemodification
site and for loading negative oligonucleotide cargos, resulting in
a sharp z-potential reversion (from 30.6 to 38.9 mV) and 30 nm
size increase. Next, the endo-bicyclo[6.1.0]nonyne-PEG4-N-hy-
droxysuccinimide (BCN-PEG4-NHS) linker was conjugated on
the PEI surface for the subsequent azido-YIGSR sequence
conjugation onto NPs via azide-alkyne bioorthogonal click
(Devaraj, 2018). The obtained YIGSR-coated NPs were still posi-
tively charged (19.2 mV), with a hydrodynamic size of 204 nm,
termed as TpNPs (short for targeting-peptide-conjugated NPs,
which were used as non-interactive NPs for control in the
follow-up experiment). Finally, the b-CDSelf-peptide was grafted
by self-assembly with YIGSR to obtain the RevSeMicNPs. The
relevant size of the NPs was 218 nm and z-potential was
9.8 mV. After loading AS411, the size of the NPs increased
8 nm and the z-potential changed to7.8 mV. The Fourier-trans-
form infrared spectroscopy (FTIR) analysis data of the prepared
NPs is listed in Figure S3B.
The drug payload test was then performed by high-perfor-
mance LC (HPLC). The loading ratio of 17-AAG and b-CDSelf-
peptide was 6.9 and 11.5 wt %, respectively. The maximum
loading degree of AS1411 was 8.2 wt%, determined using ultra-
violet-visible (UV-vis) spectroscopy. However, as the loading
amount of AS1411 affected the z-potential of NPs (Figure S3C),
we chose 5.0 wt % to obtain a slightly negative-charged surface
to reduce protein adsorption (Lundqvist et al., 2008).
Circular dichroismmeasurements were then used to test the in-
teractions between different peptide sequences (Figure 1F).
YIGSR showed a predominantly random coil structure, while
Self-peptide showed a predominantly a-helical structure, even
with b-CD terminus. Moreover, circular dichroism indicated that
the presence of b-CD did not affect the configuration of Self-pep-
tide. Furthermore, the inclusive complexes formed between Tyr
residue on YIGSR and the b-CD conjugated on Self-peptide could
significantly affect their secondary structure (Akiyoshi et al., 2000).
Therefore, the interaction between b-CDSelf-peptide and YIGSR
was confirmed, which for mixed b-CDSelf-peptide and YIGSR
showed a significant decrease in helical content (Table S1),
comparedwith themixedSelf-peptide andYIGSR. The interactionFigure 1. Characterizations of the prepared NPs
(A) The starting and ending frame of molecular dynamic simulation trajectory.
(B) The detailed interaction between experimental Self-peptide and SIRPa interfac
the key interface residues shown in stick mode.
(C) The predicted binding posed by computational docking of experimental Self-p
experimental peptide-binding poses in green and in blue individually.
(D) Hydrodynamic size, polydispersity index (PdI), and z-potential of the prepare
(E) Transmission electron microscopy (TEM) images of the obtained NPs.
(F) Circular dichroism spectroscopic data of YIGSR peptide, Self-peptide, b-CDS
equimolar mixture of YIGSR peptide and b-CDSelf-peptide.
(G) Human serum proteins adsorption onto the NPs after 1 h incubation at 37C (d
*p < 0.05, **p < 0.01, and ***p < 0.001).
(H) The cumulative release profile of 17-AAG from different types of NPs in 10%hu
of amantadine-triggered release in the group of AS1411@RevSeMicNPs + Ad.
4 Cell Reports 35, 109131, May 25, 2021between b-CDSelf-peptide and YIGSR was then confirmed by the
Ad competition test. The b-CDSelf-peptide release from NPs was
via an Ad-concentration-dependent manner (Figure S3D). Com-
bined with the Ad-relevant viability test using three kinds of cell
lines (NIH 3T3 fibroblast cells, MAD-MB-231 breast cancer cells,
and HOS-MNNG osteosarcoma cells; Figure S3E), the adopted
Ad concentration for reversing the self-mimicking on RevSe-
MicNPs in the follow-up test was 10 mg mL1.
Because the surface charge and morphology can directly
affect protein adsorption onto the surface of NPs, it was ex-
pected that the zwitterionic PEI-oligonucleotide-peptide surface
can alleviate protein corona formation, which is favorable for
reducing the immunogenicity and maintaining the autonomy of
NPs (Ashraf et al., 2016; Almalik et al., 2017; Salvati et al.,
2013). To verify this hypothesis, serum protein adsorption
amount on the different kinds of prepared NPs was investigated
with 10% human serum (Dai et al., 2014). In this comparison, the
adsorbed protein amount of bare UnPSi was set as control
(100%). As shown in Figure 1F, loading AS1411 and modifying
Self-peptide can both significantly reduce the amount of protein
adsorption. In addition, this pre-coated peptide corona may also
have similar effect as pre-coated protein corona, which can
shield from subsequent protein adsorption (Oh et al., 2018).
Next, the release profiles of 17-AAG were followed in human
serum (Figure 1G). As a result of insufficient steric hindrance
and electrostatic shielding effect from the serum proteins, drug
loaded in TpNPs suffered from burst release, with 40%
released in the first 15 min and nearly 80% released in
120 min. After modification with Self-peptide, the burst release
effect was attenuated. However, more than 50% of the drug
was still released in 4 h, after which the RevSeMicNPs showed
continuous release for the next 8 h. After loading AS1411, the
drug release amount was restrained within 20% during the
release period, suggesting that the dense, zwitterionic PEI-oligo-
nucleotide-peptide surface of the NPs can efficiently avoid the
interaction between the PSi pores and serum proteins. After
adding Ad, the protective surface layer was disintegrated and
the drug release showed a modest Ad-triggered burst release
behavior, which lasted for 1 h, after which the drug showed
slow and continuous release similar to RevSeMicNPs.
Next, the biocompatibility of the different NPs was investi-
gated using 3T3, MDA-MB-231, and HOS-MNNG cells
(Figure S3F). Overall, the UnPSi-PEI NPs showed cytotoxicity
due to the positive surface charge, but after PEG-YIGSRe by computational mimicking. Self-peptide (in cyan) and SIRPa (in green), with
eptide to SIRPa: (a) the most likely binding pose in red; (b) and (c) other possible
d NPs (data represent mean ± SD, n = 10).
elf peptide, an equimolar mixture of YIGSR peptide and Self peptide, and an
ata represent mean ± SD, n = 3; the significance level was set at probabilities of
man serum (data represent mean ±SD, n = 3). Asterisk (*) means the initial point
(legend on next page)






OPEN ACCESSmodification, the PEI cytotoxicity was reduced. However, time-
and concentration-dependent toxicity of TpNPs was still
observed. By contrast, RevSeMicNPs showed long-term
biocompatibility even at high concentrations.
Before further investigating the mechanism, western blot was
performed to determine the expression of SIRPa on the afore-
mentioned cell lines, as well as the phagocyte of RAW 264.7
macrophages (Figure S4). It was observed that all the tested cells
expressed SIRPa protein; however, the amounts in 3T3 cells and
RAW 264.7 macrophages were higher than in the other cancer
cells.
Multistage signal-interactive effect modulated NP-cell
interactions in vitro
Next, as one of the key indices for evaluating the efficiency of
NP-cell communication, targeting specificity of NPs with
different signal interfaces and the off-target effect caused by
grafting with targeting molecules was investigated (Dahlman
et al., 2017; Yu et al., 2018). In this study, four types of cell lines
(3T3,MDA-MB-231, andHOS-MNNGcells and RAW264.7mac-
rophages) were used to evaluate the uptake amount by flow cy-
tometry quantification. Five groups of different NPs—TpNPs
(positive control), TpNPs capped by b-CD (for blocking the func-
tion of Tyr, termed as TpNPsb-CD), RevSeMicNPs, TpNPsb-CD +
Ad, and RevSeMicNPs + Ad—were compared. For 3T3, MDA-
MB-231, and HOS-MNNG cells, after blocking Tyr by b-CD,
the fluorescence intensity showed a notable decrease, with an
uptake inhibition ratio of 37.4, 52.8, and 54.0% for the three
cell types, respectively. The uptake inhibition ratio of NPs that
underwent b-CDSelf-peptide blocking to the cells further
increased to 83.6, 76.9, and 81.6%, respectively. By contrast,
we found that b-CD blocking had limited effect to inhibit RAW
264.7 macrophage uptake compared with the other groups,
whereas the inhibition ratio was only 18.3%, indicating that the
b1-integrine-mediated endocytosis was not the major driving
force for the uptake of NPs by macrophages (Kuhn et al.,
2014; Behzadi et al., 2017). However, the inhibition effect of
RevSeMicNPs was more significant, which reached 91.2% for
RAW 264.7 macrophages, suggesting that reducing the immu-
nogenicity of NPs is more efficient than depriving the targeting
capacity to shield from macrophage clearance. For both
TpNPsb-CD and RevSeMicNPs, inclusion of Ad can substantially
recover the level of cell uptake efficiency to that of TpNPs, further
suggesting the effectiveness of the multistage communication
process for cell targeting modulation. The outcome of the flow
cytometry experiments was further confirmed by confocal fluo-
rescence imaging, and similar trends were found (Figure 2B).
Multistage signal-interactive NPs improved tumor
targeting in vivo
As a result of the signal-interactive induced targeting selectivity
data, an evaluation of the systematic time-dependent NPs’Figure 2. Investigation of the NP-cell interactions in vitro
(A) Flow cytometry quantitative analysis of cell uptake efficiency to NPs in Hank’s b
3; the significance level was set at probabilities of *p < 0.05, **p < 0.01, and ***p
(B) Confocal fluorescence microscopy images of cells (red: cell membranes stain
NPs; yellow: co-localization of the NPs and the cell membrane; scale bar, 20 mm
6 Cell Reports 35, 109131, May 25, 2021biodistribution and accumulation was also performed in vivo, us-
ing the HOS-MNNG tumor-bearing nude mice model. Mice were
subcutaneously injected with HOS-MNNG cells to form a xeno-
graft tumor. To test the tumor-targeting capacity of the designed
NPs, TpNPs and RevSeMicNPs loaded with AS1411 to form a
zwitterionic surface to avoid the interference of protein corona
were conjugatedwith Cy 7.5 for near-IR fluorescence tracing. Af-
ter injection by tail vein, 6 time points (3, 6, 12, 24, 48, and 72 h)
were used to investigate the real-time biodistribution of the NPs
(Figures 3A and 3B). Overall, the TpNPs-treated mice showed
clear fluorescence signal all over the body, with the highest fluo-
rescence intensity in liver. The fluorescence intensity did not
display reduction over the duration of the experiment, indicating
the non-interactive NPs had limited specificity and long-term
accumulation behavior. In addition, the tumor accumulation of
the NPs did not show an increase even after 72 h. By contrast,
the RevSeMicNPs showed significant difference of distribution
behavior in the mice. During the first 3 h, specific accumulation
in the tumor was observed, and the relevant fluorescence inten-
sity was already higher than in the liver. Furthermore, the tumor-
site-related fluorescence intensity enhanced over time, suggest-
ing the continuous accumulation behavior of the NPs. Moreover,
the fluorescence intensity in liver presented a reducing ten-
dency, indicating that unlike the TpNPs, which are rapidly
sequestered by the liver, RevSeMicNPs with self-mimicking
mechanism have efficient liver-escaping capacity. Taking
advantage of the limited liver sequestration and enhanced tumor
accumulation over time, RevSeMicNPs demonstrated significant
tumor specificity after 72 h.
The investigation of organ accumulation of NPs was then used
to quantify the amount of NPs for statistical comparison (Figures
3C and 3D, the sequence of the organs’ placement is heart, liver,
spleen, lung, kidney, and tumor). The related average radiant ef-
ficiency (avgRE) of the test organs is shown in Figure 3E. For
three time points (6, 48, and 72 h), the ratio of tumor-to-liver (ra-
tiotumor/liver) accumulation was used to determine tumor-specific
targeting of the NPs. Inconsistent with the real-time bio-
distribution, the accumulation of NPs for the TpNPs group did
not show notable time-dependent changes as a result of fast
liver sequestration. The ratiotumor/liver at 6, 48, and 72 h was
0.45, 0.40, and 0.37, respectively, whereas for the RevSeMicNPs
groups, the corresponding ratio was 0.92, 1.45, and 2.06,
respectively. Compared with the groups in same time point,
the fluorescence intensity of tumor accumulation in RevSe-
MicNPs groups was 1.3, 2.3, and 2.8 times of that in TpNPs
groups, whereas the relevant amount of liver accumulation in
RevSeMicNPs groups was 65, 62, and 51% of that in TpNPs
groups. These comparisons demonstrated that not only at an
early time but also after long-term accumulation, the NPs with
communication mechanism showed reduced liver retention
and enhanced tumor accumulation unlike the non-interactive
NPs. It is worth noting that for RevSeMicNPs groups, althoughalanced salt solution (HBSS) buffer (13, pH 7.4) (data represent mean ±SD, n =
< 0.001).
ed with CellMask Deep Red; green: fluorescein isothiocyanate (FITC)-labeled
).
(legend on next page)






OPEN ACCESSthe ratiotumor/liver was continuously increasing within 72 h, the
reduced avgRE of tumor at 72 h indicated that the amount of
accumulated NPs was less than that at 48 h. Thus, we chose
72 h as the time point for Ad injection, which will subsequently
induce the particle transformation into the active form for tumor
therapy. Furthermore, in view of the limited differences in size
and surface charge between the two types of NPs, it is reason-
able to attribute this change in the behaviors of biodistribution
and hepatic clearance to the different surface properties.
Antitumor efficacy and safety evaluation
For in vivo safety evaluation, blood tests of white blood cells
(WBCs), red blood cells (RBCs), hemoglobin (HGB), and platelets
(PLTs); liver function tests of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase (ALP),
and gamma-glutamyl transpeptidase (GGT); and kidney function
tests of creatinine (CRE) and blood urea nitrogen (BUN) were
performed to evaluate the acute toxicity at 24 h post-injection
(Figures 4A and 4B). As a result of the good biocompatibility of
the RevSeMicNPs, we chose 100 mg mL1 as the test concentra-
tion. Overall, the RevSeMicNPs-treated mice showed no obvious
difference in all tested indices compared with control group,
expect GGT. The group treated with TpNPs showed abnormal
indicator in several indices, however, not as significant as that
in the cell viability test. Especially, the decrease of RBCs and
PLTs indicated hemolytic toxicity. In addition, TpNPs induced
higher liver function index of ALT and AST, which indicates liver
damage or inflammation. Especially, the increase of ALT implies
mitochondrial damage of liver cells. By contrast, these abnormal
indicators were not observed in the RevSeMicNPs group, sug-
gesting that self-mimicking can improve the safety of the NPs
for in vivo applications.
In the antiproliferation test (Figure 4C), all the agents followed
dosage- and time-dependent therapeutic performance. Overall,
the performance of drug-loaded TpNPs (drug@TpNPs) was
better than that of other groups of free drugs, especially after
long-time incubation (48 h). The drug-loaded RevSeMicNPs
(drug@RevSeMicNPs) showed differentiable ‘‘on’’ and ‘‘off’’ cyto-
toxic behavior with/without the Ad signal. As a result of the syn-
ergetic effect of targeting depriving and self-mimicking endowed
by chimeric peptide interface, RevSeMicNPs were difficult to
uptake by cells compared with TpNPs. Thus, the cytotoxicity
of RevSeMicNPs was in the ‘‘off’’ state. After Ad triggering, NPs
converted into the targeting-active form for efficient cell uptake
and then the cytotoxicity came into ‘‘on’’ state. This is another
proof that the introduction of multistage signal-interactive mech-
anism on NPs is very promising for targeted cancer treatment
with low risks of systemic toxicity.
Next, the antitumor investigation of the NPs was performed.
Based on previous study on in vivo toxicity of the NPs and
the antiproliferation test, a nanosystem at 100 mg mL1 was
used as the test concentration. When the volume of the solid
tumor reached approximately 100 mm3, the mice receivedFigure 3. Investigation of the tumor targeting efficiency in vivo
Systemic time-dependent biodistribution of TpNPs (A) and RevSeMicNPs (B). In v
72 h post-injection with TpNPs (C) or RevSeMicNPs (D). The average fluorescence i
the significance level was set at probabilities of *p < 0.05, **p < 0.01, and ***p <
8 Cell Reports 35, 109131, May 25, 2021different treatments: saline; 17-AAG only; AS1411 only; 17-
AAG + AS1411; and drug@TpNPs, drug@RevSeMicNPs, and
drug@RevSeMicNPs with Ad intravenous injection after 72 h.
The tumors were extracted from the mice after a 35-day treat-
ment (Figure 4D), and the tumor volume was monitored during
this period. As shown in Figure 4E, the volume of tumors treated
with saline increased greatly and was approximately 46-fold
larger than its initial volume. The 17-AAG and AS1411 combina-
tion showed a synergistic effect, and the tumor volume was
found to increase only 8.3-fold over this period compared
with 15.8-fold when treated only with 17-AAG, although the syn-
ergistic effect was not obvious in cell study. While the drug-
loaded TpNPs had better antitumor activity at an early stage
than 17-AAG + AS1411, no statistical difference was observed
at the end of the test. It is worth mentioning that the tumors
treated by TpNPs had an accelerating growth speed
(Figure S5A). This may be attributed to the accelerated blood
clearance effect to the NPs (Ishihara et al., 2009; Ishida et al.,
2005). Without triggering the active targeting, drug-loaded
RevSeMicNPs showed a similar therapeutic effect as drug-
loaded TpNPs. After combining with Ad, the tumors treated
with drug-loaded RevSeMicNPs + Ad showed significant tumor
growth inhibition, of which tumors in two mice were even fully
eliminated, suggesting maximized therapeutic efficacy by the
enhanced tumor accumulation and the subsequent targeting
activation. The statistical analysis of final tumor weight is shown
in Figure S5B. The antitumor effect of the NPs without drug
loading was then investigated (Figures S5C and S5D). Gener-
ally, both TpNPs and RevSeMicNPs showed minor therapeutical
effect. For RevSeMicNPs, this is attributed to the good biocom-
patibility and homeostasis, reducing cell uptake; for TpNPs, it
is attributed to the limited tumor accumulation. Moreover, the
RevSeMicNPs + Ad group showed better antitumor efficacy,
indicating that efficient tumor accumulation by reversible self-
mimicking and in situ particle transformation can amplify the
cytotoxicity of TpNPs. However, the therapeutic efficacy was
limited compared with the drug-loaded NPs.
Hematoxylin and eosin (H&E) staining with the five major or-
gans (heart, liver, spleen, lung, and kidney) and the tumor was
also conducted to further evaluate the safety and therapeutic
efficacy of the NPs (Figure S5E). First, as a major organ of mono-
nuclear phagocyte system, liver sections were used to investi-
gate the toxicity caused by accumulation of different therapeu-
tics (Figure 4F). Significant hepatic injury was observed in the
drug@TpNPs-treated groups, and the injury degree was higher
than that of the combined drug group, indicating the significant
liver accumulation of NPs. By contrast, the self-mimicking
NPs showed distinguishable safety as no obvious nuclear
shrinkage or fragmentation was presented. On the other hand,
the RevMicNPs + Ad group showed increased safety risk, howev-
er, better than that of the combined drug group. This can be
attributed to the NPs remaining in the liver that converted into
the form of TpNPs after Ad triggering, which still have cumulativeivo imaging of five major organs and tumors harvested from mice at 6, 48, and
ntensity of the fivemajor organs and tumor (E) (data representmean ±SD, n = 3;
0.001).
(legend on next page)






OPEN ACCESStoxicity in the liver. This follow-up cytotoxicity increase can be
circumvented by optimizing the time of Ad triggering after a bet-
ter understanding of the biodistribution of NPs. Finally, the H&E
staining on tumor sections demonstrated that all types of theNP-
based therapeutics can cause extensive apoptosis in tumor cells
(Figure 4G).
DISCUSSION
In conclusion, we evaluated the targeting problem of NPs from
the perspective of communication-determined homeostasis
and developed a multistage signal-interactive system to pro-
mote the efficiency of the NP-cell communications. By intro-
ducing an interactive mechanism, the tumor-targeting capacity
of NPs can be improved by almost 3-fold, while the liver accumu-
lation can be reduced by nearly 50%. Accordingly, the tumor
weight after treatment by signal-interactive NPs is only 15.4%
of the control with obviously restricted hepatic damage. We
proved this pattern of multistage signal-interactive system can
efficiently integrate various types of signal modules and improve
the autonomy-determined homeostasis of NPs. It can be ex-
pected that the concept of ‘‘communication system’’ will emerge
as a promising platform for multivariate integration and regula-
tion of bio-signals, which means the treatment patterns can be
determined by the type of NP-cell communication, and NPs
can deeply participate in cell communications and their biolog-
ical behavior. We anticipate this strategy can inspire construc-
tion ofmore powerful therapeutic systems to promote the clinical
transition of nanomedicines.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
MDA-MB-231 and HOS-MNNG cells were cultured in RPMI 1640 medium, NIH 3T3 fibroblasts and RAW264.7 macrophages were
cultured in DMEMmedium, both supplemented with 10% v/v of fetal bovine serum (FBS), 1% nonessential amino acids, 1% l-gluta-
mine, penicillin (100 IUmL1), and streptomycin (100mgmL1). Animal model in this study is BALB/c nudemice bearing HOS-MNNG
tumors. Male BALB/c mice (20 ± 2g) were fed at the condition of 25C and 55% of humidity and approved by the Institutional Animal
Care and Use Committee of Ruijin Hospital. All animal experiments were performed in compliance with guidelines.
METHOD DETAILS
Synthesize of b-CD-BCN
The synthesize of b-CD-BCN was following previous reports (Jiang et al., 2014; Toomari et al., 2015). b-CD-OTs (264 mg, 205 mmol),
BCN-amine (100 mg, 308 mmol) and Et3N (60 mg, 600 mmol) were dissolved in dry DMF and stirring under nitrogen flow. The mixture
was heated to 70C for 24 h. Then the solvent was removed under vacuum and acetone was added to get precipitation. The precip-
itation (200 mg) was collected and used for next step without further purification. The precipitation was confirmed to be b-CD-BCN
under the characterization of Maldi-TOF. Calc. (C59H96N2O38): m/z = 1440.56, found: [M+H]
+ = 1441.32.
Synthesize of peptides
Peptide TCEVTELTREGETIIELK and GGGGYIGSR were synthesized on an automatic CEM peptide synthesizer on a scale of
250 mmol. Fmoc chemistry was applied for this synthesis and Sieber amide resin with a loading of 0.69 mmol g-1 was used. Amino
acid couplings were performed with 4 eq. of the appropriate amino acid, 4 eq. of the activator HCTU and 8 eq. of the base DIPEA.
Fmoc deprotection was performed with piperidine:DMF (4:6 v/v). After that N3-PEG4-COOH was coupled to the peptide on the resin
using 4 eq. of DIPEA and 3 eq. of HOBT in DMF overnight. Peptides were cleaved from the resin by shaking the resin with amixture of
TFA/TIS/H2O (95:2.5:2.5 v/v) for 1.5 hour. The cleavage mixture was precipitated in cold diethyl ether. Precipitate was collected and
the crude product was purified by HPLC. The pure peptides were measured and confirmed using LCMS. Peptide 1: Calc.
(C44H73N16O16): m/z = 1081.54, found: [M+H]+ = 1081.88, [M+2H]2+ = 541.36; Peptide 2: Calc. (C97H169N26O37S
+): m/z =
2322.19, found: [M+2H]2+ = 1162.76, [M+3H]3+ = 774.3 and [M+4H]4+ = 581.73.e2 Cell Reports 35, 109131, May 25, 2021
Report
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The copper-free click reaction was achieved by mixing obtained peptide 2 (1 eq., 25 mg) and b-CD-BCN (1 eq., 15 mg) in water and
stirred overnight at 40C. The solvent was evaporated on rotavapor. The obtained compounds were purified by HPLC using H2O/
ACN (gradient: 90%–10%). The peak of b-CD-peptides 2 appears at around 30%of H2O/ACN. The solution in collected peak solution
was removed by freeze-drier to obtain white powder (~5 mg). The purity of b-CD-peptides 2 was proved by HPLC trace and the mo-
lecular mass was measured using Maldi-TOF. Calc. (C156H265N28O75S
+): m/z = 3765.02, found: [m+H]+ = 3766.21.
1H NMR spectra
1H NMR spectra were measured on a Bruker AV-400MHz spectrometer. Chemical shifts were recorded in ppm. Tetramethylsilane
(TMS) is used as an internal standard. Coupling constants are given in Hz.
MALDI-TOF mass spectra
MALDI-TOF mass spectra were acquired using an Applied Biosystems Voyager System 6069 MALDI-TOF mass spectrometer.
a-Cyano-4-hydroxycinnamic acid (CHCA) was used as matrix in all cases. Sample concentrations were ~0.3 mg ml-1.
LCMS analysis
LCMS analysis was performed on a Jasco HPLC-system coupled to a Perkin Elmer Sciex API 165 mass spectrometer.
CD spectra
CD spectra were measured using a Jasco J-815 spectropolarimeter. The observed ellipticity is given in milli-degrees, the conversion




where,Qobs is the observed ellipiticity, CM is the molar total peptide concentration, l is the path length of the cuvette in cm, and N is
the number of amino acids per peptide (Zheng et al., 2013). Spectra were obtained at a sample concentration of 25 mM of peptide in
water in a 0.1 cm quartz cuvette. All measurements were made at room temperature. Data was collected at 0.2 nm intervals, at a
scanning speed of 20 nm min-1 and a 1 nm and width. Each spectrum was the average of 5 scans.
HPLC purifications of peptides
The HPLCwas performed using a Shimadzu HPLC setup equipped with two LC-8A series pumps coupled to a Shimadzu ELSD-LT II
detection system. Separation (Vydac 214 MS C4 column, 5 mm, 1003 4.6 mm, flow rate: 15 mL min-1), in all instances, was carried
out over a linear gradient of 10%–90% B over 20 min with an initial 5 min hold at 10% B. HPLC buffers: A– H2O (0.1% TFA) and B –
ACN with 0.1% trifluoroacetic acid.
Peptide docking
The necessary part of peptide with 18 amino acids structure, was sketched through Maestro. The peptide complexes with hSIRPa
were obtained via computational docking. Structural flexibility of the peptide was considered by sampling of 100 representative con-
figurations from a 100 ns long MD trajectory using Desmond (Gianti and Zauhar, 2015). Binding of the peptide to the hSIRPa was
evaluated using the docking suite Glide, the option of protocol designed specifically for peptides was ticked given its improved per-
formance (Friesner et al., 2004; Tubert-Brohman et al., 2013). The known structure of hSIRPawith cell-surface protein CD47 complex
(PDB: 2JJS) was split such that hSIRPa itself as proposed receptor of peptides, while the amino acids of CD47 at the interface plus
extended 20 Å away served as the grid definer of peptides, using the ‘‘Generate grid suitable for peptide docking’’ option. Themanual
post-docking analysis elected top three reasonable binding poses of peptide, taking the docking score into account as well to deter-
mine the most likely binding poses of the polypeptide.
Preparation of UnTHCPSi NPs
The preparation of UnTHCPSi NPs was done via electrochemical anodization, as described in detail elsewhere (Bimbo et al., 2010).
Fabrication of the multistage signal interactive system
The UnTHCPSi NPs were treated with N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide (EDC).
Briefly, 10mgof UnTHCPSi NPswas activated by 100 mL of EDC for 30min and then reactedwith 20mg of NHS in 10mLof anhydrous
dimethylformamide (DMF) for 24 h. The obtained NPswere harvested by centrifugation (Sorvall RC 5B plus, Thermo Fisher Scientific,
USA) at 13000g for 5min, thenwashed three timeswith anhydrousDMF.TheobtainedNPswas thendispersed into 10mLofDMFwith
100mg of PEI dissolved beforehand. After 12 h stirring, the obtained UnTHCPSi-PEI NPs were harvested by the aforementioned pro-
cedures. 10mg of UnTHCPSi-PEI NPs was suspended in 10mL of anhydrous DMF, then 200 mg of BCN-PEG3-NHS ester was added
into the suspension. After 24 h stirring, the obtained UnTHCPSi-PEI-BCN NPs were harvested by the aforementioned procedures.
Then 5 mg of the synthesized N3-PEG4-G4YIGSR peptide was mixed with 10 mg of UnTHCPSi-PEI-BCN NPs in 10 mL of phosphateCell Reports 35, 109131, May 25, 2021 e3
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OPEN ACCESSbuffer saline (PBS, pH 7.4, 0.01 M). After 24 h stirring, the NPs were harvested by centrifugation at 13000 g for 5 min, and washed by
PBS (pH 7.4, 0.01 M) three times. The obtained UnTHCPSi-PEI-YIGSR NPs were stocked in 75% ethanol.
The UnTHCPSi-PEI-YIGSR-b-CDSelf-peptide NPs (RevSeMicNPs) were prepared just before use. 10 mg of the UnTHCPSi-PEI-
YIGSR NPs were centrifuged and then dispersed into PBS (pH 7.4, 0.01 M), the b-CDSelf-peptide was added and then stirred 2 h.
The mass ratio of the b-CDSelf-peptide to NPs was 1:2. Then the NPs was harvested by aforementioned method.
Characterization of the NPs
The hydrodynamic size (z-average), polydispersity index (PdI) and zeta-potential (z-potential) distribution of the NPs was measured
by Zetasizer Nano ZS (Malvern Instruments Ltd.). The relevant data was recorded as the average of three measurements.
Thestructureof the fabricatedNPswascharacterizedby transmissionelectronmicroscope (TEM)underanaccelerationvoltageof120
kV. The NPs samples were prepared by depositing them onto carbon-coated copper grids (300 mesh; Electron Microscopy Sciences,
USA) and contrasting with 2% uranyl acetate solution. The NPs coated grids were dried at room temperature before the TEM imaging.
Protein adsorption of the NPs
The NPs were incubated with 10% of human serum at pH 7.4, with the final concentration of NPs at 1 mg mL1. After incubation at
37C for 2 h, 200 mL of each sample were centrifuged at 13000 g for 5 min to precipitate the protein adsorbed NPs. The protein con-
centration of supernatant was determined using UV-Vis spectroscopy (UV-1600 PB spectrophotometer, VWR) by measuring the
maximal absorbance at 280 nm wavelength. Then, the adsorbed proteins on the NPs were calculated against a standard calibration
curve of the proteins.
Drug loading degree
The loading degree of 17-AAG was tested by an immersion method. 10 mg of the prepared NPs were suspended in 1 mL of DMF in
which 25 mg 17-AAG was dissolved, and then stirred for 2 h. The supernatant then was obtained after centrifugation, and the con-
centration of 17-AAG was determined by HPLC. For HPLC, the column used for 17-AAG detection was C18 (4.6 3 100 3 3 mm,
Gemini-Nx plus C18, Phenomenex, USA), and the mobile phase used consisted of 0.2% of trifluoroacetic acid (pH 2) and ACN
(40:60, v/v) with the flow rate of 1.0 mL min1. The temperature of the column and wavelength used for drug detection were 25C
and 254 nm, respectively. The injected volume of the drug solution was 20 mL.
Helical content detecting
Helical content was determined using Equation 2:
rh =
½q222




 3 100; (Equation 2)
where, rh is the helical fraction, [q]222 is the ellipticity at 222 nm and N is the number of peptide bonds (Rabe et al., 2015).
Cell culturing
The MDA-MB-231 breast cancer cells, NIH 3T3 fibroblasts, HOS-MNNG cells and RAW264.7 macrophages were cultured in 75 cm2
flasks (Corning Inc. Life Sciences, USA) in a standard BB 16 gas incubator (Heraeus Instruments GmbH, Germany) set at 95% hu-
midity, 5% CO2, and 37
C. MDA-MB-231 and HOS-MNNG cells were cultured in standard RPMI 1640 medium, NIH 3T3 fibroblasts
and RAW264.7 macrophages were cultured in DMEM medium, both supplemented with 10% v/v of fetal bovine serum (FBS), 1%
nonessential amino acids, 1% l-glutamine, penicillin (100 IU mL1), and streptomycin (100 mg mL1) (all from HyClone, USA). Cells’
subculturing was conducted at 80% confluency, harvested prior to cell passaging and each experiment with tryp-
sinPBSethylenediaminetetraacetic acid.
Western-blotting
For protein extraction, cells at rest were washed with ice-cold PBS containing 100 mMNa3VO4 (Sigma, China), PMSF and lysed with
ice-cold lysis buffer at 4C for 15 min. Then supernatants were collected after centrifugation at 16000 g for 15 min. Concentration of
protein within lysate was determined using Folin-Lowry assay method. The extracts proteins were separated on a 7.5% SDS-PAGE
for electrophoresis. Then the cell lysate was transferred onto polyvinylidene fluoride membranes, and then blocked overnight at 4C
with 2% BSA in TBST (12.5 mM Tris/HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20). After washing with TBST, blots were incubated for
2 h at room temperature with rabbit polyclonal anti-SIRPa (Thermofisher Scientific, China) and then HRP was labeled as secondary
antibody. Membranes were washed extensively and then detected using Enhanced Chemiluminescence Plus Western-blotting
detection system (Amersham, USA).
In vitro cytotoxicity
To evaluate the biosafety of the NPs, the viability of the NIH 3T3 fibroblast, MDA-MB-231 and HOS-MNNG cells were assessed by
measuring their ATP activity after exposure to the NPs. Hundredmicroliters of the cell suspensions in cell media at a concentration ofe4 Cell Reports 35, 109131, May 25, 2021
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OPEN ACCESS23 105 cells per mLwere seeded in 96-well plates and allowed to attach overnight. After the removal of the cell media, the wells were
washed twice with HBSS–HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer (pH 7.4), and then 100 mL of the tested
NPs at the relevant concentrations was added. After incubation, the reagent assay (100 mL; CellTiter-Glo Luminescent Cell Viability
Assay, Promega, USA) was added to each well to assess the ATP activity. The luminescence was measured using a Varioskan Flash
(Thermo Fisher Scientific Inc., USA). Positive (1% Triton X-100) and negative (HBSS–HEPES buffer, pH 7.4) controls were also used
and treated similarly as described above. At least three independent measurements were conducted for each experiment.
Confocal fluorescence microscopy imaging
For the test, NIH 3T3 fibroblasts, MDA-MB-231 cells, HOS-MNNG and RAW264.7 macrophage cells were seeded in 8-chamber
slides (Nunc Lab-Tek II Chamber Slide System, Thermo Scientific, Inc., USA). For cell seeding, 200 mL of the cells suspension
(2.53 104 cells mL1) was added to each chamber. After incubation for 24 h, the cells were washed twice with HBSS–HEPES buffer
(pH 7.4). 200 mL of fluorescein isothiocyanate (FITC)– labeled NPs (10 mg mL1) was added to each chamber, and then the samples
were incubated for 6 h. After that, the cells were washed with HBSS–HEPES buffer to remove non-interacting NPs. The cell mem-
brane was stained with CellMask Deep Red (Life Technologies, USA) by incubating the cells at 37C for 3 min. Next, the cells
were washed twice with the HBSS–HEPES buffer and fixed with 2.5% of glutaraldehyde at room temperature for 20 min. Finally,
the glutaraldehyde was washed away, and the cells were stored with 200 mL of HBSS–HEPES buffer (pH 7.4). The cells were
observed under a confocal fluorescence microscope (Leica inverted SP5 II HCS A) using Ar (488 nm), HeNe (590 nm), and HeNe
(633 nm) lasers. The images were analyzed using ImageJ 1.47v (National Institute of Health, USA).
Cell uptake flow cytometry analysis
MDA-MB-231, 3T3 fibroblasts, and RAW264.7macrophage cells were seeded in 6-well plates (Corn ing Inc., Life Sciences, USA). For
cell seeding, 2.5 mL of the cells suspension (23 105 cells per mL) were added to each well. The cell culturing process was based on
the aforementioned method. After that, 1.5 mL of NPs in HBSS–HEPES buffer with the concentration of 10 mg mL1 were added to
eachwell and then the samples were incubated for relevant time. After removing the NPs suspensions andwashing twicewith HBSS–
HEPES buffer, the cells were harvested and treated with trypan blue to quench the fluorescence of NPs adhered on cell surface. Flow
cytometry was performed with a LSR II flow cytometer (BD Biosciences, USA) with a laser excitation wavelength of 488 nm using a
FACSDiva software. Ten thousand events were obtained for each sample. Relevant data were analyzed and plotted using FlowJo
software (Tree Star Inc., USA). At least three independent measurements were conducted for each experiment.
Cell growth inhibition
The cell growth inhibition performance of the developed NPs was also monitored by measuring the antiproliferation effect of the free
drug and drug-loaded NPs using the same method explained above for the cellular toxicity studies. At least three independent mea-
surements were conducted for each experiment.
Biodistribution investigation
The HOS-MNNG cells (23 106 cells per each mouse) were subcutaneously injected into the flanks of male BALB/c mice (20 ± 2g) to
construct the tumor-bearing mice. Then, the mice were injected intravenously with different therapeutics at the doses of 10 mg kg1
of NPs, which were labeled with Cy 7.5. Tissues, including heart, liver, spleen, lung, kidney, and tumor were extracted from the mice
72 h post-injection for ex vivo near infrared fluorescence (NIRF) imaging.
In vivo NIRF imaging
The prepared therapeutics were injected intravenously into the BALB/c nude mice bearing HOS-MNNG tumors at a dose of 10 mg
kg1 of NPs. Then, the mice were imaged using IVIS Lumina II with the excitation wavelength of 780 nm at 3, 6, 12, 24, 48, 72 h post-
injection. The average NIRF intensity at the tumor was calculated to describe the signals at different time points.
Ex vivo histological staining
Themice under 35-day treatment by the various formulations, including PBS, free AS1411, free 17-AAG, control-NPs, RevSemicNPs,
and RevSemicNPs+Ad were dissected. Various tissues, including heart, liver, spleen, lung, kidney, and tumor were fixed in a 4% of
formaldehyde solution for 24 h at room temperature. The various tissues were frozen and sectioned at the thickness of 10 mm. H&E
staining (BBC Biochemical, Mount Vernon, WA) was performed and observed using an IX73 bright-field microscope (Olympus).
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantitative data collected over multiple, independent experiments are presented as mean ± standard deviation (SD). At least three
independent experiments (n = 3) were performed to obtain the described results. Statistical significance of the data was analyzed by
a one-way analysis of variance (ANOVA) with Bonferroni post hoc test (GraphPad Prism, GraphPad software Inc., CA, USA). The sig-
nificance level was set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001.Cell Reports 35, 109131, May 25, 2021 e5
